Skip to main content
SpringerLink
Log in

Flavor and Taste of Lansoprazole Strawberry-Flavored Delayed-Release Oral Suspension Preferred over Ranitidine Peppermint-Flavored Oral Syrup

In Children Aged Between 5–11 Years

  • Original Research Article
  • Published:
Pediatric Drugs Aims and scope Submit manuscript

Abstract

Objective: To compare the flavor and taste preference of two acid-inhibitory therapies in healthy children aged between 5–11 years.

Methods: A single-site, single-blind, taste test trial was conducted in which 111 children participated after parental consent. One teaspoonful (5mL) of lansoprazole delayed-release oral suspension (strawberry-flavored) and ranitidine oral syrup (peppermint-flavored) were provided to each child with a 10-minute break between samples. Children tasted the sample, swished it in their mouth for 10 seconds, and then expectorated the sample. Spring water and crackers were used to clear the palate between samples. After each sampling, children were observed for facial expressions and asked to rate their degree of liking of each sample based on a 5-point facial hedonic scale (5 = like it very much, 1 = dislike it very much). Likes, dislikes, and product preference were recorded.

Results: Of the 56 female and 54 male children who tasted both samples, 95% (105/110) preferred lansoprazole. Taste and flavor were the most often cited reasons for preferring lansoprazole (61 and 17 children, respectively) while three children preferred the flavor of ranitidine oral syrup. Lansoprazole received a higher mean liking rating compared with ranitidine (mean liking scores of 4.1 and 2.2, respectively). There was no significant difference in the preference for lansoprazole between age groups and gender with the degree of liking scores ranging between 3.5–4.4. Forty-two children disliked the texture of the lansoprazole oral suspension, citing the granules (31/110), thickness (7/110), or consistency/texture (4/110), specifically.

Conclusion: After sampling both products, 95% of children preferred the flavor and taste of the strawberry-flavored lansoprazole delayed-release oral suspension compared with the peppermint-flavored ranitidine oral syrup.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Table I
Table II
Fig. 2

Similar content being viewed by others

References

  1. Nelson SP, Chen EH, Syniar GM, et al. Prevalence of symptoms of gastroesophageal reflux during childhood: a pediatric practice-based survey. Pediatric Practice Research Group. Arch Pediatr Adolesc Med 2000; 154: 150–4

    PubMed  CAS  Google Scholar 

  2. Waring JP, Feiler MJ, Hunter JG, et al. Childhood gastroesophageal reflux symptoms in adult patients. J Pediatr Gastroenterol Nutr 2002; 35: 334–8

    Article  PubMed  Google Scholar 

  3. DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease: the Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol 1999; 94: 1434–42

    Article  PubMed  CAS  Google Scholar 

  4. Freston JW, Jackson RL, Huang B, et al. Lansoprazole for maintenance of remission of erosive oesophagitis. Drugs 2002; 62(8): 1173–84

    Article  PubMed  CAS  Google Scholar 

  5. Welage LS, Berardi RR. Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases. J Am Pharm Assoc 2000; 40: 52–62

    CAS  Google Scholar 

  6. Williams MP, Pounder RE. Review article: the pharmacology of rabeprazole. Aliment Pharmacol Ther 1999; 13Suppl. 3: 3–10

    Article  PubMed  CAS  Google Scholar 

  7. Prakash A, Faulds D. Rabeprazole. Drugs 1998; 55: 261–7

    Article  PubMed  CAS  Google Scholar 

  8. Hawkey CJ, Karrasch JA, Szczepanski L, et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal anti-inflammatory drugs: Omeprazole versus Misoprostol for NSAID-Induced Ulcer Management (OMNIUM) Study Group. N Engl J Med 1998; 338: 727–34

    Article  PubMed  CAS  Google Scholar 

  9. Graham DY, Agrawal NM, Campbell DR, et al. Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs lansoprazole. Arch Intern Med 2002; 162: 169–75

    Article  PubMed  CAS  Google Scholar 

  10. Lazzaroni M, Biachi Porro G. Non-steroidal anti-inflammatory drug gastropathy: clinical results with H2 antagonists and proton pump inhibitors. Ital J Gastroenterol Hepatol 1999; 31Suppl. 1: S73–8

    PubMed  CAS  Google Scholar 

  11. Prevacid package insert. Lake Forest (IL): TAP Pharmaceutical Products, Inc., 2002 Sep

  12. Prilosec package insert. Wilmington (DE): AstraZeneca, 2002 Jul

  13. Humphries TJ, Merritt GJ. Review article: drug interactions with agents used to treat acid-related diseases. Aliment Pharmacol Ther 1999; 13Suppl. 3: 18–26

    Article  PubMed  CAS  Google Scholar 

  14. Matsui D, Lim R, Tschen T, et al. Assessment of the palatability of β-lactamase-resistant antibiotics in children. Arch Pediatr Adolesc Med 1997; 151: 599–602

    Article  PubMed  CAS  Google Scholar 

  15. Matsui D, Barron A, Rieder M. Assessment of the palatability of antistaphylococcal antibiotics in pediatric volunteers. Ann Pharmacol Ther 1996; 30: 586–8

    CAS  Google Scholar 

  16. Angelilli ML, Toscani M, Matsui DM, et al. Palatability of oral antibiotics among children in an urban primary care center. Arch Pediatr Adolesc Med 2000; 154: 267–70

    PubMed  CAS  Google Scholar 

  17. Powers JL, Gooch WM, Oddo LP. Comparison of the palatability of the oral suspension of cefdinir vs amoxicillin/clavulanate potassium, cefprozil and azithromycin in pediatric patients. Pediatr Infect Dis J 2000; 19Suppl. 12: S174–80

    PubMed  CAS  Google Scholar 

  18. Keast RS, Breslin PA. Modifying the bitterness of selected oral pharmaceuticals with cation and anion series of salts. Pharmacol Res 2002; 19: 1019–26

    Article  CAS  Google Scholar 

  19. Temple ME, Nahata MC. Comparative palatability of 22 liquid antacids. Aliment Pharmacol Ther 2000; 14(4): 421–5

    Article  PubMed  CAS  Google Scholar 

  20. Bahal-O’Mara N, Force RW, Nahata MC. Palatability of 14 over-the-counter antacids. Am Pharm 1994; NS34(1): 31–5

    PubMed  Google Scholar 

  21. Marriott C. The effect of flavour on acceptability of antacid tablets. J Clin Hosp Pharm 1983; 8(1): 69–73

    PubMed  CAS  Google Scholar 

  22. Schneider RP, Roach AC. An antacid tasting: the relative palatability of 19 liquid antacids. South Med J 1976; 69(10): 1312–3

    Article  PubMed  CAS  Google Scholar 

  23. Tyle P. Effect of size, shape and hardness of particles in suspension on oral texture and palatability. Acta Psychol (Amst) 1993; 84(1): 111–8

    Article  CAS  Google Scholar 

  24. Savarino V, Mela GS, Zentilin P, et al. Absence of tolerance in duodenal ulcer patients treated for 28 days with a bedtime dose of roxatidine or ranitidine. Fundam Clin Pharmacol 1996; 10(3): 304–8

    Article  PubMed  CAS  Google Scholar 

  25. Savarino V, Mela GS, Zentilin P, et al. Once-daily bedtime dose of roxatidine and ranitidine in acute duodenal ulcer: a combined assessment of acid inhibitory activity and healing rate. Am J Ther 1995; 2(12): 949–53

    Article  PubMed  Google Scholar 

  26. Nakashima M, Kanamaru M. Clinico-pharmacological evaluation of omeprazole, as a proton pump inhibitor, compared with H2-blockers [in Japanese]. Nippon Rinsho 1992; 50(1): 60–7

    PubMed  CAS  Google Scholar 

  27. Gough AL, Long RG, Cooper BT, et al. Lansoprazole versus ranitidine in the maintenance treatment of reflux oesophagitis. Aliment Pharmacol Ther 1996; 10(4): 529–39

    Article  PubMed  CAS  Google Scholar 

  28. Sontag SJ, Kogut DG, Fleischmann R, et al. Lansoprazole prevents recurrence of erosive reflux esophagitis previously resistant to H2-RA therapy: the Lansoprazole Maintenance Study Group. Am J Gastroenterol 1996; 91(9): 1758–65

    PubMed  CAS  Google Scholar 

  29. Cucchiara S, Minella R, Iervolino C, et al. Omeprazole and high dose ranitidine in the treatment of refractory reflux oesophagitis. Arch Dis Child 1993; 69(6): 655–9

    Article  PubMed  CAS  Google Scholar 

  30. Gunasekaran TS, Hassal EG. Efficacy and safety of omeprazole for severe gastroesophageal reflux in children. J Pediatr 1993; 123(1): 148–54

    Article  PubMed  CAS  Google Scholar 

  31. Karjoo M, Kane R. Omeprazole treatment of children with peptic esophagitis refractory to ranitidine therapy. Arch Pediatr Adolesc Med 1995; 149(3): 267–71

    Article  PubMed  CAS  Google Scholar 

  32. Israel DM, Hassal E. Omeprazole and other proton pump inhibitors: pharmacology, efficacy, and safety, with special reference to use in children. J Pediatr Gastroenterol Nutr 1998; 27(5): 568–79

    Article  PubMed  CAS  Google Scholar 

  33. Faure C, Michaud L, Shaghaghi EK, et al. Lansoprazole in children: pharmacokinetics and efficacy in reflux oesophagitis. Aliment Pharmacol Ther 2001; 15(9): 1397–402

    Article  PubMed  CAS  Google Scholar 

  34. Tolia V, Fitzgerald J, Hassall E, et al. Safety of lansoprazole in the treatment of gastroesophageal reflux disease in children. Ped Gastro Nutri 2002; 35Suppl. 4: S300–7

    Article  CAS  Google Scholar 

  35. Tolia V, Ferry G, Gunasekaran T, et al. Efficacy of lansoprazole in the treatment of gastroesophageal reflux disease in children. J Ped Gastro Nutri 2002; 35Suppl. 4: S308–18

    Article  CAS  Google Scholar 

Download references

Acknowledgments

The authors gratefully acknowledge the contributions made by Carla L. Kuesten, PhD, and the research staff at the TIAX LLC research facility in Cambridge, MA, and Susan Ruffalo, Pharm.D. of MedWrite Inc., for assistance in the preparation of the study. The study was supported by a grant from TAP Pharmaceutical Products Inc.

Author information

Authors and Affiliations

  1. Children’s Hospital of Michigan, 3901 Beaubien Boulevard, Detroit, Michigan, 48201, USA

    Vasundhara Tolia

  2. TAP Pharmaceutical Products Inc., Lake Forest, Illinois, USA

    Gary Johnston, Julie Stolle & Chang Lee

Authors
  1. Vasundhara Tolia
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gary Johnston
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Julie Stolle
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Chang Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Vasundhara Tolia.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tolia, V., Johnston, G., Stolle, J. et al. Flavor and Taste of Lansoprazole Strawberry-Flavored Delayed-Release Oral Suspension Preferred over Ranitidine Peppermint-Flavored Oral Syrup. Pediatr-Drugs 6, 127–131 (2004). https://doi.org/10.2165/00148581-200406020-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00148581-200406020-00006

Keywords

Search

Navigation